Ina Kramer

TL;DR: Results reveal a crucial novel function for osteocyte β-catenin signaling in controlling bone homeostasis in osteocyte-specific β- catenin mutants.

TL;DR: Interestingly, in vitro overexpression and RNAi-mediated knockdown experiments revealed that LRP4 specifically facilitates the previously described inhibitory action of sclerostin on Wnt1/β-catenin signaling, which identifies a novel role for L RP4 in bone.

TL;DR: PTH‐induced bone gain was blunted at all doses and skeletal sites in Sost overexpressing and deficient mice owing to attenuated bone formation rates, whereas bone resorption was not different from that in PTH‐treated wild‐type controls.

TL;DR: It is shown that MEF2 transcription factors control this enhancer and mediate inhibition of sclerostin expression by PTH.

TL;DR: This study defines a therapeutic strategy superior to the current standard of care that will reduce fractures for patients with MM.